Novel Platelet Membrane Biomimetic Nanosystems Emerge in Cancer Therapy, Offering New Hope for Patients
This innovative technology not only demonstrates significant therapeutic efficacy but also greatly reduces treatment side effects, marking a new breakthrough in the field of cancer therapy.
Technological Breakthroughs and Challenges
In the realm of nanodrug delivery systems, numerous challenges persist, including poor biocompatibility, insufficient stability in the bloodstream, imprecise targeting, and low biofilm permeability. Particularly during circulation in the blood, these systems often adsorb a large number of nonspecific proteins and biomolecules, forming a protein corona that severely impacts their ability to reach the lesion site along the intended path and exert their therapeutic effect. To address these complex issues, researchers have gradually turned their attention to the biomimetic application of various cells within the body's circulatory system. Platelet membrane biomimetic nanosystems exhibit superior biocompatibility and stability in the bloodstream and reduce protein corona formation compared to traditional nanodelivery systems, positioning them as a key solution to the challenges of drug delivery.
Based on different drug-loading methods and assembly approaches, platelet membrane biomimetic drug delivery systems can be broadly classified into three types: carriers where drugs are covalently conjugated to the platelet membrane, carriers where drugs are directly encapsulated within platelets, and nanocarriers coated with platelet membranes.
Carriers with Drugs Covalently Linked to the Platelet Membrane: These utilize natural platelets as carriers, with drugs conjugated or expressed on the platelet membrane through chemical or bioengineering methods. This type of carrier leverages platelets' ability to target regions such as tumors, circulating tumor cells (CTCs), and damaged blood vessels, delivering the drug precisely to the lesion. Subsequently, platelet activation leads to the release of drug-containing microparticles, thereby exerting the therapeutic effect.
Carriers with Drugs Directly Encapsulated Within Platelets: Drugs are encapsulated inside natural platelets using methods such as chemical treatment, electroporation, phagocytosis, hypotonic shock, or lipid fusion. This delivery approach harnesses the protective effect of platelets, not only enhancing drug stability but also reducing adverse reactions, thus improving therapeutic outcomes.
Nanocarriers Coated with Platelet Membranes: Platelet membranes are applied onto the surface of nanocarriers via electrostatic adsorption, allowing for further functional modification. This type of carrier retains purified platelet membrane proteins extracted from fresh blood, enabling the coated nanocarriers to maintain the original physiological characteristics of platelets, demonstrating significant application potential in cancer therapy and cardiovascular diseases.
Wide-Ranging Applications
The platelet membrane is rich in protein molecules, such as selectins and integrins, that bind to receptors on tumor cell surfaces. This allows platelet membrane biomimetic carriers to utilize their specific proteins for highly efficient targeting of tumor and damaged vascular regions. For instance, platelet membrane-coated silica particles can achieve targeted delivery of TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), effectively killing tumor cells. Furthermore, due to the retention of key protein components on the platelet membrane, these carriers can precisely target tumor tissue and reduce phagocytosis by scavenger cells in immunodeficient mouse models inoculated with breast cancer cells.
Synergistic Therapeutic Approaches
Additionally, platelet membrane biomimetic nanocarriers can be combined with photodynamic therapy and photothermal therapy to further enhance treatment efficacy. For example, nanocarriers co-encapsulating tungsten oxide and metformin can leverage metformin's property of reducing oxygen consumption to improve the efficacy of tungsten oxide-based photodynamic therapy. Simultaneously, the protective effect and immune evasion capability of the platelet membrane enable the nanocarriers to avoid recognition and clearance by the immune system, allowing them to exert sustained therapeutic effects at the tumor site.
Comparison with Other Carriers
Compared with cell membrane biomimetic nanocarriers derived from other cell types, platelet membrane carriers offer distinct advantages in tumor targeting and immune evasion due to their unique properties. The specific proteins expressed on their membrane enable them to target tumors expressing particular receptors and adhere specifically to areas of tumor neovascularization, achieving efficient active targeted therapy and immune evasion.
Atherosclerosis and Myocardial Infarction
Cardiovascular and cerebrovascular diseases, such as myocardial infarction, myocardial ischemia/reperfusion injury, atherosclerosis, and stroke, are common threats to human health. By enabling targeted drug delivery, platelet membrane biomimetic nanocarriers can effectively reduce atherosclerotic plaques and enhance the efficacy of vascular treatments. Using membrane fusion technology to modify cardiac stem cells with platelet nanovesicles does not interfere with the stem cells' activity and function in vitro. Instead, it enhances their binding affinity to collagen surfaces and denuded aortas, improving targeting to myocardial infarction sites and promoting stem cell accumulation in the heart.
Coagulation Disorders and Thrombolytic Therapy
Nanocarriers demonstrate high targeting efficiency in thrombolytic therapy. For instance, in the treatment of immune thrombocytopenia, such nanoparticles can retain complement binding sites on platelet surface proteins, specifically binding to antiplatelet antibodies. This prevents the release of pathological antibodies, protects circulating normal platelets, and maintains normal hemostatic function.
Diagnosis and Imaging
Utilizing platelet membrane biomimetic carriers combined with imaging probes enables real-time disease monitoring and early prevention. By integrating with imaging probes, these carriers can achieve targeted enhanced imaging. For example, a platelet membrane-coated magnetic resonance imaging (MRI) nano-contrast agent exhibits high affinity for atherosclerotic plaques, generating sufficient contrast during real-time imaging to distinguish the plaques.
Other Medical Applications
The application of platelet membrane biomimetic carriers in the medical field extends far beyond oncology and cardiovascular diseases. These carriers can be used for biological detoxification, bacterial infections, and rheumatoid arthritis treatment. For instance, one research team successfully synthesized platelet membrane nanomotors capable of efficiently adsorbing and separating platelet-targeting biologics. Experiments have demonstrated their strong affinity for platelet toxins and pathogens, offering a novel strategy for biological detoxification and the treatment of infectious diseases.
